GPS2 Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population of human A-549 cells engineered to disrupt the GPS2 gene. The polyclonal knockout format provides a heterogeneous cell mixture that enables the study of GPS2 loss-of-function effects across a range of genetic edits, reflecting population-level responses. GPS2 (G protein pathway suppressor 2) is a key transcriptional corepressor, and its targeted disruption in this model permits the investigation of derepressed gene programs in a lung carcinoma milieu.
The host A-549 cell line is a well-established human lung adenocarcinoma epithelial model derived from a 58-year-old male patient. It is widely applied in lung cancer research to examine oncogenic signaling, tumor suppressor functions, and drug response mechanisms. A-549 cells exhibit adherent growth and retain key characteristics of pulmonary epithelial cells, providing a physiologically relevant context for evaluating gene function.
GPS2 functions as a corepressor within the NCoR/SMRT complex, recruiting HDAC3 and TBL1 to mediate histone deacetylation and gene silencing. It directly inhibits c-Jun and p53 transactivation, thereby restraining AP-1-driven proliferation and p53-dependent apoptosis or cell cycle arrest. GPS2 also suppresses NF-??B signaling by binding TRAF2 and Ubc13, limiting IL-6 and TNF production. In DNA damage, GPS2 stabilizes ATM/ATR checkpoints, while in antiviral defense, it attenuates RIG-I/MAVS-mediated interferon induction. Consequently, it modulates MAPK cascades (JNK, ERK), NF-??B (p65), p53, and downstream genes like cyclin D1 and c-Myc.
Disruption of GPS2 in A-549 cells likely derepresses MAPK/AP-1 and NF-??B pathways, leading to increased phospho-c-Jun, p65 nuclear accumulation, and elevated cyclin D1 and IL-6 expression. This polyclonal knockout population mirrors inflammatory and oncogenic signaling characteristic of lung adenocarcinoma progression. The heterogeneous edits permit analysis of gene-dose effects and the identification of compensatory mechanisms that maintain viability upon corepressor loss, offering insights into potential therapeutic vulnerabilities.
Applications include Western blotting for GPS2, phospho-c-Jun, and I??B??; RT-qPCR for cyclin D1 and IL-6; luciferase reporter assays for NF-??B/AP-1 activity; immunofluorescence of p65 translocation; DNA damage assays; and antiviral pathway analysis. Cell proliferation and annexin V apoptosis assays assess functional outcomes. For further information, please contact Ascent Research.
